CME-Tagline

Mature Mood Matters: New and Emerging Developments in Geriatric Depression

neuroscienceCME Webcast

Premiere Date: Tuesday, July 23, 2013

This activity offers CE credit for:

  1. Physicians (CME)
  2. Other

All other clinicians will either receive a CME Attendance Certificate or may choose any of the types of CE credit being offered.

Credit Expiration Date: Wednesday, July 23, 2014

Faculty


J. Craig Nelson, MD J. Craig Nelson, MD 
Leon J. Epstein Professor of Geriatric Psychiatry
Director of Geriatric Psychiatry
University of California, San Francisco
San Francisco, CA

Nicole Brandt, PharmD, BCPP, CGP, FASCP Nicole Brandt, PharmD, BCPP, CGP, FASCP 
Associate Professor, Geriatric Pharmacotherapy
Director of Clinical and Educational Programs at the Peter Lamy Center
Department of Pharmacy Practice and Science
University of Maryland School of Pharmacy
Baltimore, MD

Charles F. Reynolds, III, MD Charles F. Reynolds, III, MD 
UPMC Endowed Professor in Geriatric Psychiatry
University of Pittsburgh School of Medicine
Professor of Behavioral and Community Health Sciences
Graduate School of Public Health
Pittsburgh, PA

Statement of Need

For psychiatrists who care for older patients, the premiere medical specialty meeting is the annual meeting of the American Association for Geriatric Psychiatry (AAGP). For clinicians who were not able to attend the symposium or those who did attend and wish to reinforce their learning, this enduring webcast of the live symposium at the 2013 AAGP meeting features expert faculty discussing distinct and timely “hot topics” that have implications for the care of geriatric adults with depression.

The “hot topics” covered are:

  • Measurement-based care: Measurement-based care (MBC) is at the forefront of medicine. In psychiatry, MBC requires renewed emphasis, given the release of the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), which emphasizes both the dimensional measurement of severity and the specification of medical and neurological conditions that are frequently comorbid with accompanying mood disorders.
  • The updated Beers Criteria: Released in 2012 by the American Geriatrics Society these criteria establish guidelines about the use of potentially inappropriate medications (PIMs) in older adults. A discussion of PIMs with emphasis on the safe use of psychotropic medications in older patients promotes safe prescribing practices.
  • Therapeutic advances in geriatric depression. Germane to optimal care is the ability to effectively implement therapeutic strategies that improve patient health. Clinical awareness of advances in therapeutics is important to accomplishing this goal.


  • Ellison JM, Kyomen HH, Harper DG. Depression in later life: an overview with treatment recommendations. Psychiatr Clin North Am. 2012;35(1):203-229. PMID: 22370499.

    After completing the enduring webcast, join Charles Reynolds, III, MD at 1:30 PM ET on August 21, 2013 for a live Q&A session to ask questions, pose your clinical case challenges, and to hear his insights on emerging data in the management of geriatric depression.

    Please register in advance for this live Q & A session because we will be sending reminder e-mails and information prior to the events. Do not miss this opportunity to exchange your thoughts and questions with Dr. Reynolds! Click Here to Register

    Activity Goal

    To educate on new and emerging developments in geriatric depression regarding how they influence the clinical practice of geriatric psychiatry.

    Learning Objectives

    At the end of this CE activity, participants should be able to:

    • Apply guidance about potentially inappropriate medications (PIMs) from the updated Beers Criteria to their prescribing practices in older adults with geriatric depression and common comorbidities.
    • Review DSM-5 revisions and their potential impact on the clinical management of geriatric depression, especially in terms of promoting measurement-based care.
    • Increase the percentage of patients with geriatric depression who are reassessed using a quantitative assessment tool within three months of initiating treatment.

    Target Audience

    Physicians and other healthcare professionals who care for geriatric patients with depression.

    Financial Support

    Provided by the American Association for Geriatric Psychiatry. Supported by an educational grant from Forest Research Institute, Inc., a wholly-owned subsidiary of Forest Laboratories Inc.

    Credit Information

    CME Credit (Physicians):
    The American Association for Geriatric Psychiatry (AAGP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    The American Association for Geriatric Psychiatry (AAGP) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST786 (requires free account activation), and participants can print their certificate or statement of credit immediately. This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

    Disclosure of Relevant Financial Relationships with Commercial Interests

    American Association for Geriatric Psychiatry (AAGP) and CME Outfitters, LLC, adhere to the ACCME Standards regarding commercial support of continuing medical education. It is the policy of AAGP and CME Outfitters, LLC, that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved, and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation.

    A conflict of interest is created when individuals in a position to control the content of CME have a relevant financial relationship with a commercial interest which therefore may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits.

    AAGP and CME Outfitters will identify, review, and resolve all conflicts of interest that speakers, authors or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

    Relevant financial relationships exist between the following individuals and commercial interests:

    Dr. Nelson has disclosed that he has received research support from the National Institute of Mental Health (NIMH) and Health Resource and Services Administration (HRSA). He has received lecture honoraria from (Otsuka Asia) Otsuka Pharmaceutical Co., Ltd. He serves as a consultant to Bristol-Myers Squibb Company; Cenestra Health; Corcept Therapeutics; Eli Lilly and Company; Medtronic, Inc.; Mylan Inc. (Dey Pharma); Otsuka America, Inc.; Pfizer Inc.; Sunovion Pharmaceuticals Inc.; and Theracos, Inc. He serves on the advisory board of Eli Lilly and Company and discloses stock ownership in Atossa Genetics, Inc.

    Dr. Brandt has no disclosures to report.

    Dr. Reynolds has disclosed that he has received research support from American Association of Geriatric Psychiatry-Editorial Review Board Fee; Grants support from National Institute of Health (NIH): National Institute of Mental Health (NIMH); National Institute on Aging (NIA); National Institute on Minority Health and Health Disparities (NIMHD); National Heart, Lung, and Blood Institute (NHLBI); Centers for Medicare & Medicaid Services (CMS); John A. Hartford Foundation; American Foundation for Suicide Prevention; Commonwealth of Pennsylvania; Patient-Centered Outcomes Research Institute (PCORI); American Association for Geriatric Psychiatry (AAGP)-Associate Editor; Bristol-Meyers Squibb Company, Forrest Labs; Eli Lilly and Company; Pfizer Inc.-Provides pharmaceutical supplies for NIH-sponsored work. (The pharmaceutical companies play no role in the design, analysis, or reporting of my data in peer reviewed journals.) He is a Licensed Intellectual Property (co-inventor) Psychometric analysis of the Pittsburgh Sleep Quality Index (PSQI) PRO10050447, PI: Dr. Daniel Buysse.

    Christine M. deVries (AAGP staff - planning committee) has nothing to disclose

    Marjorie Vanderbilt (AAGP staff - planning committee) has nothing to disclose

    Daniel Bateman, MD (content/peer reviewer) has nothing to disclose.

    David Beck, MD (content/peer reviewer) has nothing to disclose.

    Tatyana P. Shteinlukht, MD, PhD (content/peer reviewer) has nothing to disclose.

    Monique Johnson, MD, CCMEP (planning committee) has nothing to disclose.

    Joy Bartnett Leffler, MLA, NASW, CSE (planning committee) has nothing to disclose.

    Sandra Haas Binford, MAEd (planning committee) has nothing to disclose.

    Sharon Tordoff, CCMEP (planning committee) has nothing to disclose.

    Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

    AAGP, CME Outfitters, LLC, the faculty, and Forest Laboratories do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

    Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


    This document was last modified on:

    MMV-045-072313-03